{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,5,20]],"date-time":"2026-05-20T17:14:45Z","timestamp":1779297285974,"version":"3.51.4"},"reference-count":38,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2025,8,29]],"date-time":"2025-08-29T00:00:00Z","timestamp":1756425600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"},{"start":{"date-parts":[[2025,8,29]],"date-time":"2025-08-29T00:00:00Z","timestamp":1756425600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Sci Rep"],"DOI":"10.1038\/s41598-025-17371-w","type":"journal-article","created":{"date-parts":[[2025,8,29]],"date-time":"2025-08-29T08:35:07Z","timestamp":1756456507000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":1,"title":["MicroRNAs as prognostic and predictive biomarkers among chronic myeloid leukemia patients in Addis Ababa, Ethiopia"],"prefix":"10.1038","volume":"15","author":[{"given":"Fekadu","family":"Urgessa","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Isaac","family":"Jenkins","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Aster","family":"Tsegaye","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Helen","family":"Nigussie","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Teklu","family":"Kuru","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Amha","family":"Gebremedhin","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Fozia","family":"Abdela","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Fisihatsion","family":"Tadesse","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jerald","family":"Radich","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2025,8,29]]},"reference":[{"key":"17371_CR1","doi-asserted-by":"crossref","first-page":"32","DOI":"10.3389\/fcell.2019.00032","volume":"7","author":"V Gambacorta","year":"2019","unstructured":"Gambacorta, V., Glani, D., Vago, L. & Di Micco, R. Epigenetic therapies for acute myeloid leukemia and their immune-related effects. Front. Cell Dev. 7, 32 (2019).","journal-title":"Front. Cell Dev."},{"key":"17371_CR2","doi-asserted-by":"publisher","first-page":"13","DOI":"10.1016\/j.exphem.2016.11.005","volume":"47","author":"CJ Clarke","year":"2017","unstructured":"Clarke, C. J. & Holyoake, T. L. Preclinical approaches in chronic myeloid leukemia: From cells to systems. Exp. Hematol. 47, 13\u201323 (2017).","journal-title":"Exp. Hematol."},{"issue":"6","key":"17371_CR3","doi-asserted-by":"publisher","first-page":"1709","DOI":"10.3390\/jcm9061709","volume":"9","author":"D Russo","year":"2020","unstructured":"Russo, D., Garcia-Gutierrez, J. V., Soverini, S. & Baccarani, M. Chronic myeloid leukemia prognosis and therapy: Criticisms and perspectives. J. Clin. Med. 9(6), 1709 (2020).","journal-title":"J. Clin. Med."},{"issue":"6","key":"17371_CR4","doi-asserted-by":"publisher","first-page":"477","DOI":"10.1097\/PPO.0b013e318237e5b7","volume":"17","author":"DW Woessner","year":"2011","unstructured":"Woessner, D. W., Lim, C. S. & Deininger, M. W. Development of an effective therapy for chronic myelogenous leukemia. Cancer J. 17(6), 477\u2013486 (2011).","journal-title":"Cancer J."},{"key":"17371_CR5","doi-asserted-by":"publisher","first-page":"665","DOI":"10.3389\/fonc.2019.00665","volume":"9","author":"PE Westerweel","year":"2019","unstructured":"Westerweel, P. E. & Te Boekhorst, P. A. W. New approaches and treatment combinations for the management of chronic myeloid leukemia. Front. Oncol. 9, 665 (2019).","journal-title":"Front. Oncol."},{"key":"17371_CR6","doi-asserted-by":"publisher","first-page":"16","DOI":"10.1177\/11795549221139357","volume":"4","author":"B Yohanan","year":"2022","unstructured":"Yohanan, B. & George, B. Current management of chronic myeloid leukemia myeloid blast phase. Clin. Med. Insights Oncol. 4, 16. https:\/\/doi.org\/10.1177\/11795549221139357 (2022).","journal-title":"Clin. Med. Insights Oncol."},{"key":"17371_CR7","unstructured":"National Comprehensive Cancer Network. NCCN Clinical Practice Guidelines in Oncology: Chronic Myelogenous Leukemia. Version 1, 2026. https:\/\/www.nccn.org\/professionals\/ physician_gls\/pdf\/cml.pdf. Accessed 26 July 2025 (2025)."},{"key":"17371_CR8","doi-asserted-by":"crossref","unstructured":"Chuang, J.C. & Jones, P.A. Epigenetics and microRNAs. Pediatric Res. 61(5 Part 2), 24R-9R (2007).","DOI":"10.1203\/pdr.0b013e3180457684"},{"issue":"12","key":"17371_CR9","doi-asserted-by":"publisher","first-page":"2785","DOI":"10.1002\/ijc.29347","volume":"137","author":"C Basse","year":"2015","unstructured":"Basse, C. & Arock, M. The increasing roles of epigenetics in breast cancer: Implications for pathogenicity, biomarkers, prevention and treatment. Int. J. Cancer 137(12), 2785\u20132794 (2015).","journal-title":"Int. J. Cancer"},{"key":"17371_CR10","doi-asserted-by":"publisher","first-page":"57","DOI":"10.1186\/s12943-020-01175-9","volume":"19","author":"AA Bhat","year":"2020","unstructured":"Bhat, A. A. et al. Role of non-coding RNA networks in leukemia progression, metastasis and drug resistance. Mol. Cancer 19, 57 (2020).","journal-title":"Mol. Cancer"},{"issue":"5","key":"17371_CR11","doi-asserted-by":"publisher","first-page":"263","DOI":"10.1080\/10245332.2015.1114766","volume":"21","author":"X Li","year":"2016","unstructured":"Li, X. & Zhong, H. The diagnosis, prognosis, and therapeutic application of microRNAs in haematological malignancies. Hematology 21(5), 263\u2013271 (2016).","journal-title":"Hematology"},{"issue":"6","key":"17371_CR12","doi-asserted-by":"publisher","first-page":"278","DOI":"10.1002\/ddr.21266","volume":"76","author":"K Kotagama","year":"2015","unstructured":"Kotagama, K., Chang, Y. & Mangone, M. miRNAs as biomarkers in chronic myelogenous leukemia. Drug Dev. Res. 76(6), 278\u2013285 (2015).","journal-title":"Drug Dev. Res."},{"issue":"1","key":"17371_CR13","doi-asserted-by":"publisher","first-page":"53","DOI":"10.1186\/1755-8794-7-53","volume":"7","author":"RA Rawlings-Goss","year":"2014","unstructured":"Rawlings-Goss, R. A., Campbell, M. C. & Tishkoff, S. A. Global population-specific variation in miRNA associated with cancer risk and clinical biomarkers. BMC Med. Genomics 7(1), 53 (2014).","journal-title":"BMC Med. Genomics"},{"key":"17371_CR14","doi-asserted-by":"publisher","first-page":"286","DOI":"10.1186\/s12864-021-07542-0","volume":"22","author":"S Guo","year":"2021","unstructured":"Guo, S. et al. Variation of microRNA expression in the human placenta driven by population identity and sex of the newborn. BMC Genomics 22, 286. https:\/\/doi.org\/10.1186\/s12864-021-07542-0 (2021).","journal-title":"BMC Genomics"},{"key":"17371_CR15","unstructured":"Xpert BCR-ABL Ultra 302-0738 Rev. C. https:\/\/web-support.cepheid.com (2021)."},{"key":"17371_CR16","doi-asserted-by":"publisher","unstructured":"Giai, V. et al. CML patients who fail to achieve \u2264 1% BCR::ABL1 at 12 months or \u2264 0.1% BCR::ABL1 at 24 months (major molecular response, MMR) show significantly inferior survival, but not due to CML-related deaths: Data from an Italian Real-Life Observational Study. Blood 144, 3155\u20133157. https:\/\/doi.org\/10.1182\/blood-2024-207877 (2024).","DOI":"10.1182\/blood-2024-207877"},{"key":"17371_CR17","unstructured":"R Core Team. R: A Language and Environment for Statistical Computing. https:\/\/www.R-project.org (R Foundation for Statistical Computing, 2025)."},{"key":"17371_CR18","unstructured":"Aboyoun, P. & Ortogero, N. NanoString NC Tools: NanoString nCounter Tools.. NanoString NC Tools. NanoString NC Tools, R Package Version 1.12.0. https:\/\/bioconductor.org\/packages\/NanoStringNCTools (2024)."},{"issue":"7","key":"17371_CR19","doi-asserted-by":"publisher","DOI":"10.1093\/nar\/gkv007","volume":"43","author":"ME Ritchie","year":"2015","unstructured":"Ritchie, M. E. et al. limma powers differential expression analyses for RNA-sequencing and microarray studies. Nucleic Acids Res. 43(7), e47 (2015).","journal-title":"Nucleic Acids Res."},{"key":"17371_CR20","doi-asserted-by":"publisher","first-page":"545","DOI":"10.1186\/s12859-019-3105-x","volume":"20","author":"V Licursi","year":"2019","unstructured":"Licursi, V., Conte, F., Fiscon, G. & Paci, P. MIENTURNET: An interactive web tool for microRNA-target enrichment and network-based analysis. BMC Bioinform. 20, 545. https:\/\/doi.org\/10.1186\/s12859-019-3105-x (2019).","journal-title":"BMC Bioinform."},{"issue":"3","key":"17371_CR21","doi-asserted-by":"publisher","first-page":"442","DOI":"10.1002\/ajh.25011","volume":"93","author":"E Jabbour","year":"2018","unstructured":"Jabbour, E. & Kantarjian, H. Chronic myeloid leukemia: 2018 update on diagnosis, therapy and monitoring. Am. J. Hematol. 93(3), 442\u2013459 (2018).","journal-title":"Am. J. Hematol."},{"key":"17371_CR22","doi-asserted-by":"publisher","first-page":"8191","DOI":"10.3390\/ijms25158191","volume":"25","author":"D Barbagallo","year":"2024","unstructured":"Barbagallo, D. et al. MiR-223-3p in cancer development and cancer drug resistance: SameCoin, different faces. Int. J. Mol. Sci. 25, 8191. https:\/\/doi.org\/10.3390\/ijms25158191 (2024).","journal-title":"Int. J. Mol. Sci."},{"key":"17371_CR23","doi-asserted-by":"publisher","unstructured":"Gilicze, A.B. et al. Myeloid-derived microRNAs, miR-223, miR27a, and miR-652, are dominant players in myeloid regulation. BioMed Res. Int. 870267, 1\u20139. https:\/\/doi.org\/10.1155\/2014\/870267 (2014).","DOI":"10.1155\/2014\/870267"},{"key":"17371_CR24","doi-asserted-by":"publisher","unstructured":"Kadkhoda, S. & Ghafouri\u2011Fard, S. The importance of miRNA\u2011630 in human diseases with an especial focus on cancers. Cancer Cell Int. 22, 105. https:\/\/doi.org\/10.1186\/s12935-022-02531-z (2022).","DOI":"10.1186\/s12935-022-02531-z"},{"key":"17371_CR25","doi-asserted-by":"publisher","first-page":"37","DOI":"10.1186\/s12943-016-0518-2","volume":"15","author":"CH Yeh","year":"2016","unstructured":"Yeh, C. H., Moles, R. & Nicot, C. Clinical significance of microRNAs in chronic and acute human leukemia. Mol. Cancer 15, 37. https:\/\/doi.org\/10.1186\/s12943-016-0518-2 (2016).","journal-title":"Mol. Cancer"},{"issue":"2","key":"17371_CR26","doi-asserted-by":"publisher","first-page":"159","DOI":"10.4149\/BLL_2020_023","volume":"12","author":"M Yurt","year":"2020","unstructured":"Yurt, M., Ayyildiz, O., Karakus, A., Nursal, A. F. & Isi, H. MicroRNAs expression profiles as biomarkers and therapeutic tools in Turkish patients with chronic myeloid leukemia. Bratisl Med. J. 12(2), 159\u2013163 (2020).","journal-title":"Bratisl Med. J."},{"key":"17371_CR27","doi-asserted-by":"crossref","unstructured":"Di Stefano, C., Mirone, G., Perna, S. & Marfe, G. The roles of microRNAs in the pathogenesis and drug resistance of chronic myelogenous leukemia (review). Oncol. Rep. 35, 614\u2013624 (2016).","DOI":"10.3892\/or.2015.4456"},{"key":"17371_CR28","doi-asserted-by":"publisher","DOI":"10.3389\/fcell.2021.640587","volume":"9","author":"W Li","year":"2021","unstructured":"Li, W. et al. MicroRNA-34a: Potent tumor suppressor, cancer stem cell inhibitor, and potential anticancer therapeutic. Front. Cell Dev. Biol. 9, 640587. https:\/\/doi.org\/10.3389\/fcell.2021.640587 (2021).","journal-title":"Front. Cell Dev. Biol."},{"key":"17371_CR29","doi-asserted-by":"publisher","first-page":"26","DOI":"10.1186\/s40164-020-00183-1","volume":"9","author":"T Kl\u00fcmper","year":"2020","unstructured":"Kl\u00fcmper, T. et al. Expression diferences of miR-142-5p between treatment-na\u00efve chronic myeloid leukemia patients responding and non-responding to imatinib therapy suggest a link to oncogenic ABL2, SRI, cKIT and MCL1 signaling pathways critical for development of therapy resistance. Exp. Hematol. Oncol. 9, 26. https:\/\/doi.org\/10.1186\/s40164-020-00183-1 (2020).","journal-title":"Exp. Hematol. Oncol."},{"issue":"49","key":"17371_CR30","first-page":"1","volume":"60","author":"H Sun","year":"2022","unstructured":"Sun, H. et al. TRIB2 regulates the expression of miR-33a-5p through the ERK\/c-Fos pathway to affect the imatinib resistance of chronic myeloid leukemia cells. Int. J. Oncol. 60(49), 1\u201312 (2022).","journal-title":"Int. J. Oncol."},{"issue":"40","key":"17371_CR31","doi-asserted-by":"publisher","first-page":"1","DOI":"10.3390\/biom13010040","volume":"13","author":"W Huang","year":"2023","unstructured":"Huang, W. et al. The regulatory mechanism of miR-574-5p expression in cancer. Biomolecules 13(40), 1\u201321. https:\/\/doi.org\/10.3390\/biom13010040 (2023).","journal-title":"Biomolecules"},{"issue":"6","key":"17371_CR32","doi-asserted-by":"publisher","first-page":"949","DOI":"10.4149\/neo_2015_115","volume":"62","author":"D Jurkovicova","year":"2015","unstructured":"Jurkovicova, D. et al. MicroRNA expression profiling as supportive diagnostic and therapy prediction tool in chronic myeloid leukemia. Neoplasma 62(6), 949\u2013958. https:\/\/doi.org\/10.4149\/neo_2015_115 (2015).","journal-title":"Neoplasma"},{"key":"17371_CR33","doi-asserted-by":"publisher","unstructured":"Hironaka-Mitsuhashi, A. et al. MiR-1285\u20135p\/TMEM194A axis affects cell proliferation in breast cancer. Cancer Sci. 111, 395\u2013405. https:\/\/doi.org\/10.1111\/cas.14287 (2020).","DOI":"10.1111\/cas.14287"},{"issue":"9","key":"17371_CR34","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0044398","volume":"7","author":"Q Wang","year":"2012","unstructured":"Wang, Q. et al. Plasma miR-601 and miR-760 are novel biomarkers for the early detection of colorectal cancer. PLoS ONE 7(9), e44398. https:\/\/doi.org\/10.1371\/journal.pone.0044398 (2012).","journal-title":"PLoS ONE"},{"key":"17371_CR35","doi-asserted-by":"publisher","first-page":"256","DOI":"10.3390\/cancers14010256","volume":"14","author":"A Schwarz","year":"2022","unstructured":"Schwarz, A., Roeder, I. & Seifert, M. Comparative gene expression analysis reveals similarities and differences of chronic myeloid leukemia phases. Cancers 14, 256. https:\/\/doi.org\/10.3390\/cancers14010256 (2022).","journal-title":"Cancers"},{"key":"17371_CR36","doi-asserted-by":"publisher","first-page":"4820","DOI":"10.3390\/cancers13194820","volume":"13","author":"R Alves","year":"2021","unstructured":"Alves, R. et al. Resistance to tyrosine kinase inhibitors in chronic myeloid leukemia\u2014From molecular mechanisms to clinical relevance. Cancers 13, 4820. https:\/\/doi.org\/10.3390\/cancers13194820 (2021).","journal-title":"Cancers"},{"key":"17371_CR37","doi-asserted-by":"publisher","first-page":"12516","DOI":"10.3390\/ijms222212516","volume":"22","author":"B Abdulmawjood","year":"2021","unstructured":"Abdulmawjood, B., Costa, B., Roma-Rodrigues, C., Baptista, P. V. & Fernandes, A. R. Genetic biomarkers in chronic myeloid leukemia: What have we learned so far?. Int. J. Mol. Sci. 22, 12516. https:\/\/doi.org\/10.3390\/ijms222212516 (2021).","journal-title":"Int. J. Mol. Sci."},{"key":"17371_CR38","doi-asserted-by":"publisher","first-page":"4987","DOI":"10.2147\/CMAR.S314343","volume":"13","author":"L Wang","year":"2021","unstructured":"Wang, L., Li, L., Chen, R., Huang, X. & Ye, X. Understanding and monitoring chronic myeloid leukemia blast crisis: How to better manage patients. Cancer Manag. Res. 13, 4987\u20135000 (2021).","journal-title":"Cancer Manag. Res."}],"container-title":["Scientific Reports"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41598-025-17371-w.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41598-025-17371-w","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41598-025-17371-w.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,9,9]],"date-time":"2025-09-09T20:35:16Z","timestamp":1757450116000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41598-025-17371-w"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,8,29]]},"references-count":38,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2025,12]]}},"alternative-id":["17371"],"URL":"https:\/\/doi.org\/10.1038\/s41598-025-17371-w","relation":{},"ISSN":["2045-2322"],"issn-type":[{"value":"2045-2322","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,8,29]]},"assertion":[{"value":"14 July 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"22 August 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"29 August 2025","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The authors declare no competing interests.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}},{"value":"The study was approved by the College Institutional Review Board (IRB), College of Health Science, Addis Ababa University (protocol number 026\/21\/lab) before starting the study. In addition, the study was reviewed by the hematology unit, and internal medicine departmental ethical committee before starting the data collection. Further, before sending the sample to the collaborator Institute, Fred Hutchinson Cancer Research Center, we have granted national ethical clearance from the National Research Ethics Review Committee (NRERC) (Ref no 03\/246\/951\/22). All the procedures have been conducted according to the Declaration of Helsinki. Informed consent was taken from all the leukemic patients before starting blood sample collection. For those who cannot read and write cases, we tried to make everything clear to them by reading the information sheet and consent form to understand the aim of the study and to participate voluntarily. Finally, all privacy of the study population is kept secret.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}}],"article-number":"31844"}}